.jpg){kind=small}
Perspective Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2401 Elliott Ave Ste 320, Seattle, Washi...Phone Number
(206) 676-0900Revenue
-Stock Symbol
CATXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Perspective Therapeutics
Perspective Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative radiopharmaceutical therapies for the treatment of cancer. The company specializes in targeted alpha-particle therapy, an emerging field of precision oncology that combines advanced radiochemistry with molecular targeting technologies to deliver highly localized radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. Through scientific innovation and clinical research, Perspective Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers by creating therapies capable of delivering potent therapeutic effects with greater precision than conventional radiation approaches.Explore more
Perspective Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Perspective Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Perspective Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Perspective Therapeutics launches new products
Check out if Perspective Therapeutics is spiking on competitors!
Earning: See what the market has to say on Perspective Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Perspective Therapeutics has new funding data
Perspective Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Perspective Therapeutics
Click to see if Perspective Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Perspective Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Perspective Therapeutics
Compare insights from companies similar to Perspective Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$65.5M
201-500
Private
$418M
2020
SC
Sudhakar ChintharlapalliVice President, Head of Biology and Translational
Company Profile Activity
Activity Insights
Perspective Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Perspective Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Perspective Therapeutics.
Perspective Therapeutics financials insights
Gather financial insights about Perspective Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$18M
2021
Grant
$5M
Perspective Therapeutics Tech Stack
A closer look at the technologies used by Perspective Therapeutics
Most Recent Scoops
Open Position
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Perspective Therapeutics News & Media
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company’s ongoing Phase 1/2a study.Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in ChPerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics, Inc. (CATX) Bank of America Global Healthcare Conference 2026 May 13, 2026 5:20 PM EDTCompany ParticipantsJoel Sendek - CFO &...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Perspective Therapeutics
Sign Up For FreeTo access detailed company insights
Perspective Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative radiopharmaceutical therapies for the treatment of cancer. The company specializes in targeted alpha-particle therapy, an emerging field of precision oncology that combines advanced radiochemistry with molecular targeting technologies to deli... Read More
